Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

The Cleveland Clinic73 enrolled

Overview

RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.

OBJECTIVES: * Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib. * Determine the progression-free and overall survival of patients treated with this drug. OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for survival. PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Brain and Central Nervous System Tumors

Interventions

erlotinib hydrochlorideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically confirmed glioblastoma multiforme * Radiographic evidence of recurrence or progression * Biopsies to confirm tumor recurrence allowed if a sufficent percentage of cases are confirmed to be recurrent tumor * Previously treated with optimal radiotherapy and at least 1 cytotoxic chemotherapy regimen PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin no greater than 2 times normal * Alkaline phosphatase no greater than 2 times normal * ALT no greater than 3 times normal Renal * BUN no greater than 1.5 times normal OR * Creatinine no greater than 1.5 times normal Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No medical condition that would interfere with oral administration of erlotinib * No other medical or psychiatric illness that would preclude study therapy * No active infection * No other malignancy within the past 3 years except surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunotherapy for brain cancer * No concurrent biologic therapy for brain cancer Chemotherapy * See Disease Characteristics * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered * No concurrent chemotherapy for brain cancer Endocrine therapy * Concurrent glucocorticosteroids allowed * No concurrent hormonal therapy for brain cancer Radiotherapy * See Disease Characteristics Surgery * Not specified Other * No prior epidermal growth factor receptor (EGFR) inhibitor * No concurrent EGFR inhibitor * No other concurrent antineoplastic therapy * No concurrent anti-epileptic agents other than modest- or non-enzyme-inducing drugs such as the following: * Gabapentin * Lamotrigine * Divalproex * Felbamate * Levetiracetam * Tiagabine * Topiramate * Zonisamide

Locations (1)

Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, United States

RECRUITING

Outcomes

Primary Outcomes

Response rate

Secondary Outcomes

Progression-free survival

Overall survival

Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling

Efficacy of tumor EGFR amplification in predicting response to treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.